epocrates logo
epocrates logo
epocrates logo
  • 0

Interaction Check

epocrates logo

Sign in to access our clinical decision support tools

Sign in Create Account

Selected Drugs Clear All

  • remove Exforge
    amlodipine/ valsartan
  • remove MoviPrep
    polyethylene glycol/ electrolytes/ sodium ascorbate/ ascorbic acid
  • remove Uniretic
    moexipril/ hydrochlorothiazide

multicheck MultiCheck Results - 5 Interactions

Smiley face Smiley face

Avoid/Use Alternative

Smiley face Smiley face Exforge (amlodipine/ valsartan) + Uniretic (moexipril/ hydrochlorothiazide)

Avoid/Use Alternative


valsartan + moexipril

use alternative or monitor BP, renal fxn, electrolytes: combo may incr. risk of hypotension, hyperkalemia, renal impairment without additional benefit (additive effects, dual blockade of renin-angiotensin-aldosterone system)

Monitor/Modify Tx


valsartan + hydrochlorothiazide

monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

Monitor/Modify Tx

Smiley face Smiley face Exforge (amlodipine/ valsartan) + MoviPrep (polyethylene glycol/ electrolytes/ sodium ascorbate/ ascorbic acid)

Monitor/Modify Tx


valsartan + polyethylene glycol/ electrolytes

monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

Smiley face Smiley face MoviPrep (polyethylene glycol/ electrolytes/ sodium ascorbate/ ascorbic acid) + Uniretic (moexipril/ hydrochlorothiazide)

Monitor/Modify Tx


polyethylene glycol/ electrolytes + hydrochlorothiazide

monitor renal fxn, sodium, potassium, consider monitoring ECG: combo may incr. risk of renal impairment, hyponatremia, seizures, hypokalemia, QT prolongation, cardiac arrhythmias (additive effects)

polyethylene glycol/ electrolytes + moexipril

monitor renal fxn: combo may incr. risk of renal impairment (additive effects)

Additional Considerations

Smiley face Smiley face amlodipine in Exforge

levamlodipine is the active isomer of racemic amlodipine; similar interactions anticipated

Smiley face Smiley face polyethylene glycol/electrolytes in MoviPrep

separate administration from other oral drugs by at least 1h; polyethylene glycol/electrolytes may decr. absorption of concomitant oral drugs

Help
FDA Reporting Form
 
Download Epocrates from the App Store Download Epocrates from the Play Store
About Us Features Business Solutions Help & Feedback
© 2026 epocrates, Inc.    Terms of Use Privacy Policy Editorial Policy Do Not Sell or Share My Information